Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, BioArctic AB's Enterprise Value is kr27,741 Mil.
BioArctic AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was kr244 Mil. Therefore, BioArctic AB's EV-to-OCF for today is 113.70.
The historical rank and industry rank for BioArctic AB's EV-to-OCF or its related term are showing as below:
LTS:0RV2'
s EV-to-OCF Range Over the Past 10 Years
Min: -2232.15 Med: -40.25 Max: 193.96
Current: 113.7
During the past 11 years, the highest EV-to-OCF of BioArctic AB was 193.96. The lowest was -2232.15. And the median was -40.25.
LTS:0RV2's EV-to-OCF is ranked worse than 97.58% of 1407
companies
in the Biotechnology industry
Industry Median: -3.7
vs LTS:0RV2: 113.70
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BioArctic AB's PE Ratio (TTM) for today is calculated as:
BioArctic AB's share price for today is kr338.90.
BioArctic AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr1.180.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
BioArctic AB EV-to-OCF Related Terms
BioArctic AB EV-to-OCF Historical Data
* Premium members only.
The historical data trend for BioArctic AB's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0RV2 vs VRTX, REGN, MRNA: EV-to-OCF Comparison
For the Biotechnology subindustry, BioArctic AB's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioArctic AB EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioArctic AB's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where BioArctic AB's EV-to-OCF falls into.
BioArctic AB's current Enterprise Value is kr27,741 Mil.
BioArctic AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr244 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioArctic AB (LTS:0RV2) has a EV-to-OCF of 113.70 as of Sep. 06, 2026. According to the industry distribution chart, BioArctic AB ranks #1373 out of 1407 companies in the Biotechnology industry, placing it in the top 97.6%.
Is BioArctic AB's EV-to-OCF too high?
BioArctic AB's current EV-to-OCF is 113.70. Based on the distribution chart, BioArctic AB ranks #1373 out of 1407 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BioArctic AB has a GF Score™ of 75/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioArctic AB's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioArctic AB ranks #1373 out of 1407 companies for EV-to-OCF. This places BioArctic AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. BioArctic AB's current EV-to-OCF is 113.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioArctic AB stock overvalued right now?
Based on GuruFocus' analysis, BioArctic AB (LTS:0RV2) is currently considered Possible Value Trap. The stock's GF Value™ is kr491.21, compared to a current price of kr338.90 — trading 31% below its estimated fair value. The current EV-to-OCF is 113.70. BioArctic AB's overall GF Score™ is 75/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For BioArctic AB (LTS:0RV2), the current EV-to-OCF is 113.70 as of Sep. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioArctic AB (LTS:0RV2) Overvalued in 2026?
Based on GuruFocus' analysis, BioArctic AB stock appears to be undervalued.
The current stock price of kr338.90 is trading 31% below its estimated GF Value™ of kr491.21.
GuruFocus considers BioArctic AB to be Possible Value Trap.
Key valuation signals for LTS:0RV2:
EV-to-OCF: 113.70
GF Value™: kr491.21 vs. price of kr338.90 (31% below fair value)
No single metric tells the full story. See the LTS:0RV2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioArctic AB is a research-based biopharmaceutical company focusing on disease-modifying treatments and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and ALS. Geographically, it derives a majority of its revenue from North America.
75GF Score
Get the complete analysis for LTS:0RV2
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RV2 has been successfully added to your 
